Sun Pharma's ILUMYA Wins US Approval for Psoriatic Arthritis, Giving Up to 2.4 Million Americans a Clinic-Administered Treatment Option

India's largest drugmaker has secured a significant expansion of its most important specialty medicine in the United States, opening a new market among patients with a painful and often debilitating form of arthritis.

The US Food and Drug Administration has approved ILUMYA (tildrakizumab-asmn), Sun Pharmaceutical Industries' biologic drug, for the treatment of adults with active psoriatic arthritis, the company announced on Friday, October 30, according to Pharmaceutical Executive. The drug was first approved in 2018 for moderate-to-severe plaque psoriasis.

Sun Pharma's shares gained on the news, with the Nifty Pharma index rising 1.8% on the day, according to HDFC Sky.

What psoriatic arthritis is

Psoriatic arthritis is a chronic inflammatory disease that affects some people with psoriasis, a skin condition that causes red, scaly patches. It causes joint pain, stiffness and swelling, and can lead to permanent joint damage if untreated. Sun Pharma estimates that up to 2.4 million Americans live with psoriatic arthritis, and that roughly one in three people with psoriasis also have the condition.

More than 15% of people with psoriasis may have undiagnosed psoriatic arthritis, according to the company, highlighting the need for greater awareness among patients and doctors.

The clinical evidence

The approval was based on two phase 3 trials, INSPIRE-1 and INSPIRE-2, which compared ILUMYA 100 mg with placebo over 52 weeks in more than 800 participants. INSPIRE-1 enrolled patients who had previously received a TNF inhibitor, a common class of arthritis drugs, while INSPIRE-2 enrolled patients who had not.

Sun Pharma reported in 2025 that both studies met their primary endpoint, ACR20 at week 24, a standard measure of at least 20% improvement in arthritis symptoms. Detailed response rates are expected to be presented at a medical meeting and in a publication, according to Pharmaceutical Executive. The company reported no new safety signals, with upper respiratory tract infections among the most common side effects.

A different delivery model

ILUMYA is administered by a healthcare provider rather than self-injected by patients at home, which Sun Pharma is positioning as a differentiator. "Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment," said Rick Ascroft, chief executive of Sun Pharma North America.

Some patients struggle with self-injection because of joint pain, dexterity problems or anxiety, and a clinic-administered option with infrequent dosing may suit them. Philip Mease, director of rheumatology research at Swedish Medical Center and Providence St Joseph Health, said: "we need a range of therapeutic options that allow us to individualize care."

How the drug works

Tildrakizumab is a monoclonal antibody that targets interleukin-23 (IL-23), a protein involved in the inflammatory processes that drive psoriasis and psoriatic arthritis. IL-23 inhibitors have become an important class of treatment for psoriatic disease, alongside TNF inhibitors and IL-17 inhibitors.

Competition

The psoriatic arthritis market is large and competitive. Established treatments include TNF inhibitors such as Humira and its biosimilars, IL-17 inhibitors such as Cosentyx and Taltz, and other IL-23 inhibitors such as Tremfya and Skyrizi, which are already approved for psoriatic arthritis. Oral targeted therapies are also available.

Competing against drugs from much larger companies, including AbbVie, Johnson & Johnson, Novartis and Eli Lilly, will be challenging. Sun Pharma's provider-administered positioning and pricing will be important factors in gaining market share. Launch timing and pricing have not been disclosed.

Sun Pharma's specialty strategy

Sun Pharma, founded by Dilip Shanghvi, built its business on generic medicines but has invested heavily in specialty drugs, which carry higher margins and are less exposed to the price erosion that affects generics. ILUMYA is the cornerstone of its specialty portfolio, alongside dermatology and oncology products.

Specialty products have become an increasingly important share of Sun Pharma's US revenue, reducing its dependence on generics. The psoriatic arthritis approval could significantly expand ILUMYA's market.

Global approvals

ILUMYA is approved for psoriasis in India, Australia, Canada, China and Japan, and in Europe, where it is marketed by Almirall as Ilumetri, according to Pharmaceutical Executive.

Why it matters for Indian pharma

The approval highlights the evolution of India's pharmaceutical industry from a producer of low-cost generics to a developer and marketer of innovative specialty medicines. Indian drugmakers are increasingly investing in research, in-licensing and acquisitions to build specialty portfolios in the United States, the world's largest pharmaceutical market.

The US specialty market

The United States is the world's largest market for specialty medicines, and success there can transform the economics of an Indian drugmaker. Specialty drugs require dedicated sales forces, relationships with specialist doctors and negotiations with insurers and pharmacy benefit managers, which control access to medicines. Sun Pharma has built a specialty sales infrastructure in the United States over the past decade, focused on dermatology and oncology.

Pricing and insurance coverage are critical. Biologic drugs are expensive, and insurers often require patients to try cheaper options first. The arrival of biosimilar versions of older drugs, such as Humira, has increased competition and pricing pressure in immunology.

The in-office advantage

Sun Pharma's emphasis on provider administration could appeal to certain patients and doctors. Some rheumatology practices administer biologic drugs in their clinics, and in-office administration can be reimbursed differently from self-injected drugs dispensed by pharmacies. ILUMYA's infrequent dosing schedule, with maintenance doses every 12 weeks for psoriasis, makes clinic visits more manageable for patients.

India's pharma ambitions

The approval adds to a series of milestones for Indian pharmaceutical companies in innovative and specialty medicines. Companies including Glenmark, Dr Reddy's, Zydus and Biocon have developed or acquired specialty products and biosimilars for global markets. The government has encouraged research-led growth through policies supporting pharmaceutical innovation, aiming to move the industry beyond its traditional strength in generics.

What comes next

Sun Pharma will now prepare to launch ILUMYA for psoriatic arthritis in the United States. Its success will depend on pricing, insurance coverage, physician adoption and the strength of the full trial data. For investors, the approval strengthens the outlook for Sun Pharma's specialty business, which has become a key driver of its growth.

Doctors and patients will also be looking closely at the full trial data when it is published, since it will determine how ILUMYA compares with existing treatments and where it fits in clinical practice for patients with psoriatic arthritis.

For investors, the approval adds to the momentum in Sun Pharma's specialty business, which has become an increasingly important driver of the company's growth and profitability as competition in the US generics market continues to put pressure on prices and margins.